Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 vs chemotherapy in EGFR-mutant NSCLC
NCT01646125Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of Luminespib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Nov 2012; status: terminated.
02
Drugs
Luminespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01646125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646125.